Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00943800 · ClinicalTrials.gov registry record · NA
Combined Haploidentical-Cord Blood Transplantation for Adults and Children
A NA study, sponsored by University of Chicago.
- Completed
- Registry status
- NA
- Development phase
- 87
- Enrollment target
NCT00943800: Completed NA study, sponsored by University of Chicago.
NCT00943800 is a NA study that has completed, run by University of Chicago. The registered enrollment target is 87 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00943800, a NA study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 87 participants
- Enrollment target
Study Summary
The primary objective is to assess the rate of engraftment with combined haploidentical-cord blood transplantation. The secondary objective is to evaluate the incidence and severity of acute and chronic graft-versus-host disease (GVHD).
Primary Outcome
Cumulative incidence of graft failure (neutrophil) by day 28 was reported. Patients who did not have neutrophil engraftment before death was considered as a competing risk. Failure to engraft was defined as lack of evidence of hematopoietic recovery (ANC \<500/mm3 and platelet count \< 20,000/mm3) by day +35, confirmed by a biopsy revealing a marrow cellularity \< 5%. Graft failure was also defined as initial myeloid engraftment by day +35, documented to be of donor origin, followed by a drop in
Interventions
- PROCEDURE Stem Cell Transplant
- DRUG Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)
- PROCEDURE Stem Cells Collections
- DRUG Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)
- DRUG Fludarabine, Busulfan, and ATG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2006-10-09 |
| Est. Completion | 2018-09 |
| Phase | NA |
What the finished NCT00943800 record still lists
NCT00943800 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 5 interventions - of which Stem Cell Transplant is the first listed.
NCT00943800 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00943800 about?
NCT00943800 is a clinical study titled "Combined Haploidentical-Cord Blood Transplantation for Adults and Children". The primary objective is to assess the rate of engraftment with combined haploidentical-cord blood transplantation. The secondary objective is to evaluate the incidence and severity of acute and chronic graft-versus-host disease (GVHD).
What is the current status of trial NCT00943800?
This trial is currently completed. It is a NA study. The enrollment target is 87 participants. The study started on 2006-10-09. Estimated completion is 2018-09.
What interventions are being tested in trial NCT00943800?
The interventions under investigation include: Stem Cell Transplant (PROCEDURE), Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG) (DRUG), Stem Cells Collections (PROCEDURE), Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI) (DRUG), Fludarabine, Busulfan, and ATG (DRUG).
Who is sponsoring clinical trial NCT00943800?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00943800's enrollment target sits among peer trials
87 974th of 2000 higher than 1,025 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI